PAM
ACOR

Paradigm Asset Management’s Acorda Therapeutics ACOR Stock Holding History

Paradigm Asset Management’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-18
Closed -$43.3K – 534
2017
Q2 		$43.3K Sell
18
-20
-53% -$39.6K 0.01% 534
2017
Q1 		$94.5K Buy
38
+3
+9% +$8.63K 0.02% 532
2016
Q4 		$79K Sell
35
-1
-3% -$2.38K 0.02% 450
2016
Q3 		$89.8K Buy
+36
New +$107K 0.02% 452
2015
Q1 		– Sell
-209
Closed -$1.02M – 856
2014
Q4 		$1.02M Sell
209
-12
-5% -$51.5K 0.13% 191
2014
Q3 		$900K Buy
221
+6
+3% +$22.5K 0.13% 197
2014
Q2 		$868K Buy
215
+10
+5% +$40.8K 0.12% 202
2014
Q1 		$934K Sell
205
-16
-7% -$64.7K 0.13% 196
2013
Q4 		$775K Buy
221
+24
+12% +$93.6K 0.12% 217
2013
Q3 		$811K Sell
197
-13
-6% -$56K 0.13% 194
2013
Q2 		$833K Buy
+210
New +$865K 0.14% 196

Other funds holding ACOR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Paradigm Asset Management's ACOR Position: Q3 2017 in Review

Paradigm Asset Management sold out of Acorda Therapeutics (ACOR) in Q3 2017, closing a stake of 18 shares — an estimated $43.3K sold.

Paradigm Asset Management first reported a position in ACOR in Q2 2013 and held it in 11 quarters. The position peaked at $1.02M in Q4 2014. 152 funds tracked by Wall St. Rank hold ACOR as of Q3 2017.

  • Paradigm Asset Management reported no remaining Acorda Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Paradigm Asset Management sold 18 Acorda Therapeutics shares in Q3 2017, an estimated $43.3K.
  • Paradigm Asset Management first reported a position in Acorda Therapeutics in Q2 2013 and held it in 11 quarters.
  • Paradigm Asset Management's Acorda Therapeutics position peaked at $1.02M in Q4 2014.
  • 152 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q3 2017.

Based on Paradigm Asset Management's 13F filing for Q3 2017, filed 14 Nov 2017.